|
|
 |
|
Viewing report
|
|
|
|
European Asthma Therapeutics Markets
Frost & Sullivan, July 2007, Pages: 82
This Frost & Sullivan research service titled European Asthma Therapeutics Markets provides key challenges, forecasts and recommendations for the asthma therapeutics market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: short acting beta 2 agonists, inhaled corticosteroids, combination therapies and leukotriene antagonists.
Increasing Incidence of Asthma Triggers Spiraling Growth of the European Asthma Therapeutics Markets
One of the major contributors of the pharmaceuticals industry’s revenues is the respiratory market, which is primarily driven by the asthma therapeutics market. A major factor powering the growth of the asthma therapeutics market, which contributes as high as 75 percent of the respiratory market’s revenues, is the growing population affected with asthma and chronic obstructive pulmonary disease (COPD) in member states of the European Union (EU).
Increasing pollution levels and changing environment are prodding the incidence of respiratory diseases. About 50 per cent of the asthmatic population in Europe suffers from mild or intermittent asthma. Scotland has the highest prevalence rate with about 18 per cent of the population suffering from asthma. 'As the incidence of respiratory diseases is reaching epidemic proportions, the market for respiratory medication in Europe is likely to grow,' notes the analyst of this research service. 'With increase in the economic burden of asthma, novel drugs and delivery systems are bound to become a cash cow for the manufacturers.'
Educational Campaigns to Increase Awareness among Patients and Their Compliance with Treatments
Though present-day drugs have been in the market for long and generating high revenues, they do not meet the needs of the diseased population. Introduction of new products that provide a cure or at least better control of the exacerbations is the current requirement in the market. 'However, only 42 per cent of the patient population in Europe has very few or no emergency visits to the clinic for asthma, reflecting the large number of people who have not been catered to for their needs,' cites the analyst. The misuse or inefficient use of respiratory drugs leads to poor patient satisfaction and reduced compliance with treatments. Marketing campaigns aimed at increasing awareness about asthma is the sole remedy for increasing patient compliance and market penetration.
Moreover, the importance of the label and the indication for which a drug is filed and approved has become a contentious issue after the Xolair ambiguity, where the US and the EU labels were different. Regulatory trends such as the pediatric regulation can be instrumental in filing new applications, as there is a mandate for separate clinical trials for pediatric formulations.
|
|
|
|
